These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. High prevalence of subclinical cardiovascular abnormalities in patients with systemic lupus erythematosus in spite of a very low clinical damage index. Palmieri V, Migliaresi P, Orefice M, Lupo T, Di Minno MN, Valentini G, Celentano A. Nutr Metab Cardiovasc Dis; 2009 May; 19(4):234-40. PubMed ID: 19157818 [Abstract] [Full Text] [Related]
4. Association of improvement of brachial artery flow-mediated vasodilation with cardiovascular events. Suessenbacher A, Frick M, Alber HF, Barbieri V, Pachinger O, Weidinger F. Vasc Med; 2006 Nov; 11(4):239-44. PubMed ID: 17390547 [Abstract] [Full Text] [Related]
6. Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: an 8 weeks controlled trial. Ferreira GA, Navarro TP, Telles RW, Andrade LE, Sato EI. Rheumatology (Oxford); 2007 Oct; 46(10):1560-5. PubMed ID: 17693444 [Abstract] [Full Text] [Related]
7. Assessment of premature atherosclerosis in systemic lupus erythematosus patients with and without nephritis. Sharma SK, Rathi M, Sahoo S, Prakash M, Dhir V, Singh S. Lupus; 2016 Apr; 25(5):525-31. PubMed ID: 26678442 [Abstract] [Full Text] [Related]
10. Endothelial dysfunction and cardiovascular risk prediction in peripheral arterial disease: additive value of flow-mediated dilation to ankle-brachial pressure index. Brevetti G, Silvestro A, Schiano V, Chiariello M. Circulation; 2003 Oct 28; 108(17):2093-8. PubMed ID: 14530195 [Abstract] [Full Text] [Related]
11. Endothelium-dependent and independent dilation capability of peripheral arteries in patients with systemic lupus erythematosus and antiphospholipid syndrome. Stalc M, Tomsic M, Jezovnik MK, Poredos P. Clin Exp Rheumatol; 2011 Oct 28; 29(4):616-23. PubMed ID: 21813059 [Abstract] [Full Text] [Related]
12. Endothelial function and markers of endothelial activation in relation to cardiovascular disease in systemic lupus erythematosus. Svenungsson E, Cederholm A, Jensen-Urstad K, Fei GZ, de Faire U, Frostegård J. Scand J Rheumatol; 2008 Oct 28; 37(5):352-9. PubMed ID: 18666029 [Abstract] [Full Text] [Related]
14. Novel cardiovascular risk factors and cardiac event predictors in female inactive systemic lupus erythematosus patients. Karadag O, Calguneri M, Atalar E, Yavuz B, Akdogan A, Kalyoncu U, Bilgen SA, Ozer N, Ertenli AI, Ovunc K, Kiraz S. Clin Rheumatol; 2007 May 28; 26(5):695-9. PubMed ID: 16909327 [Abstract] [Full Text] [Related]
15. A controlled comparison of brachial artery flow mediated dilation (FMD) and digital pulse amplitude tonometry (PAT) in the assessment of endothelial function in systemic lupus erythematosus. Aizer J, Karlson EW, Chibnik LB, Costenbader KH, Post D, Liang MH, Gall V, Gerhard-Herman MD. Lupus; 2009 Mar 28; 18(3):235-42. PubMed ID: 19213862 [Abstract] [Full Text] [Related]
17. Plasminogen activator inhibitor-1 is associated with impaired endothelial function in women with systemic lupus erythematosus. Somers EC, Marder W, Kaplan MJ, Brook RD, McCune WJ. Ann N Y Acad Sci; 2005 Jun 28; 1051():271-80. PubMed ID: 16126968 [Abstract] [Full Text] [Related]